



## HIV und antiretrovirale Therapie

1. Hütter G, Nowak D, Mossner M, Ganepola S, Müssig A, Allers K, Schneider T, Hofmann J, Kücherer C, Blau O *et al*: **Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation.** *N Engl J Med* 2009, **360**(7):692-698, DOI: [10.1056/NEJMoa0802905](https://doi.org/10.1056/NEJMoa0802905).
2. Gupta RK, Peppas D, Hill AL, Gálvez C, Salgado M, Pace M, McCoy LE, Griffith SA, Thornhill J, Alrubayyi A *et al*: **Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report.** *Lancet HIV* 2020, **7**(5):e340-e347, DOI: [10.1016/S2352-3018\(20\)30069-2](https://doi.org/10.1016/S2352-3018(20)30069-2).
3. Diaz R, *et al*: **The first long-term remission of chronic HIV-1 infection without myeloablation?** In: *23rd International AIDS Conference 2020*, abstract OAXLB0105.
4. Yarchoan R, Klecker RW, Weinhold KJ, Markham PD, Lyerly HK, Durack DT, Gelmann E, Lehrman SN, Blum RM, Barry DW *et al*: **Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex.** *Lancet* 1986, **1**(8481):575-580, DOI: [10.1016/s0140-6736\(86\)92808-4](https://doi.org/10.1016/s0140-6736(86)92808-4).
5. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT *et al*: **The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.** *N Engl J Med* 1987, **317**(4):185-191, DOI: [10.1056/nejm198707233170401](https://doi.org/10.1056/nejm198707233170401).
6. [No authors listed]: **Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee.** *Lancet* 1996, **348**(9023):283-291, DOI: [S0140673696053871 \[pii\]](https://doi.org/S0140673696053871).
7. Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT: **Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.** *Nature* 1993, **361**(6413):650-654, DOI: [10.1038/361650a0](https://doi.org/10.1038/361650a0).
8. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D *et al*: **A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study.** *JAMA* 1998, **279**(12):930-937, DOI: [joc71782 \[pii\]](https://doi.org/joc71782).
9. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Jr., Feinberg JE, Balfour HH, Jr., Deyton LR *et al*: **A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.** *N Engl J Med* 1997, **337**(11):725-733, DOI: [10.1056/NEJM199709113371101](https://doi.org/10.1056/NEJM199709113371101).
10. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD: **Decay characteristics of HIV-1-infected compartments during combination therapy.** *Nature* 1997, **387**(6629):188-191, DOI: [10.1038/387188a0](https://doi.org/10.1038/387188a0).
11. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N: **Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.** *Ann Intern Med* 2000, **133**(1):21-30, DOI: [10.7326/0003-4819-133-1-200007040-00004](https://doi.org/10.7326/0003-4819-133-1-200007040-00004).



12. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE: **Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance.** *Clin Infect Dis* 2003, **37**(8):1112-1118, DOI: [10.1086/378301](https://doi.org/10.1086/378301).
13. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA *et al*: **Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.** *Antimicrob Agents Chemother* 1997, **41**(3):654-660, DOI: [10.1128/aac.41.3.654](https://doi.org/10.1128/aac.41.3.654).
14. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B *et al*: **Class-sparing regimens for initial treatment of HIV-1 infection.** *N Engl J Med* 2008, **358**(20):2095-2106, DOI: [10.1056/NEJMoa074609](https://doi.org/10.1056/NEJMoa074609).
15. Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, Zhao J, Xu X, Williams-Diaz A, Rodgers AJ *et al*: **Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naïve patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial.** *Lancet* 2009, **374**(9692):796-806, DOI: [10.1016/S0140-6736\(09\)60918-1](https://doi.org/10.1016/S0140-6736(09)60918-1).
16. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, Hocqueloux L, Maggiolo F, Sandkovsky U, Granier C *et al*: **Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.** *N Engl J Med* 2013, **369**(19):1807-1818, DOI: [10.1056/NEJMoa1215541](https://doi.org/10.1056/NEJMoa1215541).
17. Ryom L, Cotter A, De Miguel R, Béguelin C, Podlekareva D, Arribas JR, Marzolini C, Mallon P, Rauch A, Kirk O *et al*: **2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.** *HIV Med* 2020, **21**(10):617-624, DOI: [10.1111/hiv.12878](https://doi.org/10.1111/hiv.12878).
18. D'Amico R, Margolis DA: **Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection.** *Curr Opin HIV AIDS* 2020, **15**(1):13-18, DOI: [10.1097/coh.0000000000000606](https://doi.org/10.1097/coh.0000000000000606).
19. Link JO, Rhee MS, Tse WC, Zheng J, Somoza JR, Rowe W, Begley R, Chiu A, Mulato A, Hansen D *et al*: **Clinical targeting of HIV capsid protein with a long-acting small molecule.** *Nature* 2020, **584**(7822):614-618, DOI: [10.1038/s41586-020-2443-1](https://doi.org/10.1038/s41586-020-2443-1).
20. Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P *et al*: **Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.** *N Engl J Med* 2020, **382**(13):1232-1243, DOI: [10.1056/NEJMoa1902493](https://doi.org/10.1056/NEJMoa1902493).
21. Kleinpeter AB, Freed EO: **HIV-1 Maturation: Lessons Learned from Inhibitors.** *Viruses* 2020, **12**(9), DOI: [10.3390/v12090940](https://doi.org/10.3390/v12090940).
22. Chahine EB, Durham SH: **Ibalizumab: The First Monoclonal Antibody for the Treatment of HIV-1 Infection.** *Ann Pharmacother* 2021, **55**(2):230-239, DOI: [10.1177/1060028020942218](https://doi.org/10.1177/1060028020942218).

## Fälle und Fallstricke

23. Gottlieb MS, Schroff R, Schanker HM, Weisman JD, Fan PT, Wolf RA, Saxon A: **Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.** *N Engl J Med* 1981, **305**(24):1425-1431, DOI: [10.1056/nejm198112103052401](https://doi.org/10.1056/nejm198112103052401).



24. Zaman MK, White DA: **Serum lactate dehydrogenase levels and Pneumocystis carinii pneumonia. Diagnostic and prognostic significance.** *Am Rev Respir Dis* 1988, **137**(4):796-800, DOI: [10.1164/ajrccm/137.4.796](https://doi.org/10.1164/ajrccm/137.4.796).
25. Tasaka S, Tokuda H, Sakai F, Fujii T, Tateda K, Johkoh T, Ohmagari N, Ohta H, Araoka H, Kikuchi Y *et al*: **Comparison of clinical and radiological features of pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study.** *Internal medicine (Tokyo, Japan)* 2010, **49**(4):273-281, DOI: [10.2169/internalmedicine.49.2871](https://doi.org/10.2169/internalmedicine.49.2871).
26. Tominski D, Katchanov J, Driesch D, Daley MB, Liedtke A, Schneider A, Slevogt H, Arastéh K, Stocker H: **The late-presenting HIV-infected patient 30 years after the introduction of HIV testing: spectrum of opportunistic diseases and missed opportunities for early diagnosis.** *HIV Med* 2017, **18**(2):125-132, DOI: [10.1111/hiv.12403](https://doi.org/10.1111/hiv.12403).
27. Shrobbree J, Campbell LJ, Ibrahim F, Hopkins P, Vizcaychipi M, Strachan S, Post FA: **Late HIV diagnosis is a major risk factor for intensive care unit admission in HIV-positive patients: a single centre observational cohort study.** *BMC Infect Dis* 2013, **13**:23, DOI: [10.1186/1471-2334-13-23](https://doi.org/10.1186/1471-2334-13-23).
28. Gazzard B, Clumeck N, d'Arminio Monforte A, Lundgren JD: **Indicator disease-guided testing for HIV--the next step for Europe?** *HIV Med* 2008, **9 Suppl 2**:34-40, DOI: [10.1111/j.1468-1293.2008.00592.x](https://doi.org/10.1111/j.1468-1293.2008.00592.x).
29. Dickinson L, Yapa HM, Jackson A, Moyle G, Else L, Amara A, Khoo S, Back D, Karolia Z, Higgs C *et al*: **Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.** *Antimicrob Agents Chemother* 2015, **59**(10):6080-6086, DOI: [10.1128/AAC.01441-15](https://doi.org/10.1128/AAC.01441-15).
30. Crauwels HM, van Heeswijk RP, Buelens A, Stevens M, Boven K, Hoetelmans RM: **Impact of food and different meal types on the pharmacokinetics of rilpivirine.** *J Clin Pharmacol* 2013, **53**(8):834-840, DOI: [10.1002/jcph.107](https://doi.org/10.1002/jcph.107).
31. Zhu L, Persson A, Mahnke L, Eley T, Li T, Xu X, Agarwala S, Dragone J, Bertz R: **Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.** *J Clin Pharmacol* 2011, **51**(3):368-377, DOI: [10.1177/0091270010367651](https://doi.org/10.1177/0091270010367651).
32. Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, Mangin E, Marbury TC, Berg JK, Chodakewitz JA *et al*: **Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.** *Antimicrob Agents Chemother* 2009, **53**(7):2852-2856, DOI: [10.1128/aac.01468-08](https://doi.org/10.1128/aac.01468-08).